title: New antithrombotic drugs: a revolution in stroke management.
authors.affiliation: Division of Neurology and Stroke Unit, Groote Schuur Hospital and University of Cape Town, South Africa. Alan.Bryer@uct.ac.za
authors.forename: A
authors.initials: A
authors.lastname: Bryer
mesh_terms: D001562:Benzimidazoles / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D017277:Drug Approval; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008991:Monitoring, Physiologic; D009025:Morpholines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D000069552:Rivaroxaban; D020521:Stroke / Q000188:drug therapy* / Q000191:economics; D013876:Thiophenes / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran